RenovoRx Announces Promising Pharmacokinetic Data Using the TAMP™ Platform Presented at the 2026 ASCO Annual Meeting
RenovoRx said a Phase III TIGeR-PaC PK/pharmacodynamic sub-study abstract was published for the 2026 ASCO meeting. The study in 16 patients compared intra-arterial gemcitabine via its TAMP/RenovoCath system (IAG) versus IV gemcitabine, reporting lower systemic gemcitabine and higher inactive metabolite levels, with a correlation to reduced CA 19-9. The company expects full enrollment in June 2026 and final readout mid-to-late 2027.
How this was made
The 30-second read
Why it matters
The company is using ASCO to reinforce the mechanism: intra-arterial micro-perfusion to increase local potency while lowering systemic gemcitabine exposure and related side effects, with CA19-9 reductions as supportive evidence.
Market read
Favorable PK/PD and biomarker-linked findings can improve perceived probability of clinical success for RNXT’s drug-device combination, but it is not the final efficacy readout.
What to watch
Small sample size (16 patients) and sub-study design mean results could be sensitive to site/patient variability; investors may discount until full TIGeR-PaC primary endpoints are reported.
Background
RenovoRx is commercializing RenovoCath (FDA-cleared device) and testing IAG (gemcitabine delivered via RenovoCath) in Phase III TIGeR-PaC for locally advanced pancreatic cancer.
Ticker impact
RenovoRx reported Phase III TIGeR-PaC PK/PD sub-study showing intra-arterial gemcitabine via RenovoCath may reduce systemic exposure and CA19-9.
Near-term bias to the upside on biotech sentiment, with follow-through dependent on full Phase III efficacy endpoints in 2027.
The release highlights favorable biomarker-linked PK/PD relationships (CA19-9 reduction) but is a small sub-study (16 patients) and not the primary efficacy dataset.
Market effects
Supports the broader targeted drug-delivery theme (local administration to reduce systemic toxicity) that can lift sentiment for adjacent medtech/drug-device combo developers.
Primarily US-focused oncology investor attention around ASCO; limited direct regional spillover beyond biotech indices.
ASCO data is globally visible, but the impact is most likely confined to small-cap oncology delivery peers until larger efficacy readouts emerge.
Counterpoint
PK/PD biomarker signals (CA19-9) may not translate into statistically significant survival/response benefits required for approval.
Key entities
- companyRenovoRx, Inc.
Announced ASCO-published PK/PD sub-study results for IAG delivered via RenovoCath in TIGeR-PaC.
- productRenovoCath
FDA-cleared device for targeted intra-arterial delivery/temporary vessel occlusion used to enable IAG.
- clinical_trialTIGeR-PaC
Ongoing Phase III trial comparing intra-arterial gemcitabine vs intravenous gemcitabine; sub-study reports PK/PD.
- eventASCO Annual Meeting 2026
Conference where the abstract is presented, potentially driving near-term investor attention.
